NICE Endorses Obecabtagene Autoleucel Therapy f...

By João L. Carapinha

November 25, 2025

NICE Backs Obecabtagene Autoleucel The National Institute for Health and Care Excellence (NICE) recommended obecabtagene autoleucel therapy, a UK-dev...
Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Rethinking Health Technology Assessment: Evolving Economic Evaluations for Fa...
NICE HealthTech Methods Update
Global Health Technology Assessment: Navigating NICE’s Role and Challen...
Revolutionizing Pharmacoeconomic Evaluations Nederland: Zorginstituut’s...
NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patie...
Talquetamab Multiple Myeloma: Impact, Evidence, and Policy Considerations
NICE Rejects Donanemab: Treatment Cost-Effectiveness
Blinatumomab Benefit Assessment for ALL and Health Economics
NICE HealthTech Reforms: Accelerating Digital Innovation in NHS and Global He...
NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment...
Evolving NICE Health Technology Evaluations: Enhancing Patient Perspectives a...